IRIS
LARONI, ALICE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.291
AS - Asia 1.483
NA - Nord America 890
SA - Sud America 116
AF - Africa 29
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 13.811
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 11.063
US - Stati Uniti d'America 829
SG - Singapore 614
CN - Cina 411
VN - Vietnam 249
FR - Francia 99
BR - Brasile 70
BD - Bangladesh 47
HK - Hong Kong 46
DE - Germania 26
MX - Messico 25
FI - Finlandia 24
AR - Argentina 23
CA - Canada 22
IQ - Iraq 18
JP - Giappone 17
GB - Regno Unito 14
NL - Olanda 13
IN - India 12
CH - Svizzera 11
ES - Italia 9
PH - Filippine 9
PK - Pakistan 9
ID - Indonesia 8
JM - Giamaica 7
EC - Ecuador 6
KE - Kenya 6
ZA - Sudafrica 6
CL - Cile 5
AZ - Azerbaigian 4
IE - Irlanda 4
KR - Corea 4
MA - Marocco 4
SA - Arabia Saudita 4
BO - Bolivia 3
DZ - Algeria 3
JO - Giordania 3
LT - Lituania 3
OM - Oman 3
PY - Paraguay 3
RS - Serbia 3
RU - Federazione Russa 3
TH - Thailandia 3
UA - Ucraina 3
BH - Bahrain 2
CO - Colombia 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
HR - Croazia 2
IL - Israele 2
KZ - Kazakistan 2
MY - Malesia 2
NP - Nepal 2
RO - Romania 2
SI - Slovenia 2
TN - Tunisia 2
TR - Turchia 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AO - Angola 1
AT - Austria 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BG - Bulgaria 1
CG - Congo 1
CV - Capo Verde 1
EE - Estonia 1
EG - Egitto 1
GA - Gabon 1
GF - Guiana Francese 1
GT - Guatemala 1
HT - Haiti 1
HU - Ungheria 1
IR - Iran 1
KG - Kirghizistan 1
LB - Libano 1
LU - Lussemburgo 1
MM - Myanmar 1
MN - Mongolia 1
NI - Nicaragua 1
PE - Perù 1
PL - Polonia 1
PS - Palestinian Territory 1
PT - Portogallo 1
SE - Svezia 1
SL - Sierra Leone 1
SO - Somalia 1
SY - Repubblica araba siriana 1
TW - Taiwan 1
UZ - Uzbekistan 1
XK - ???statistics.table.value.countryCode.XK??? 1
YT - Mayotte 1
Totale 13.811
Salva come PNG Salva come JPEG
Città #
Genova 5.668
Genoa 3.519
Vado Ligure 967
Rapallo 781
San Jose 298
Singapore 264
Ashburn 101
Lauterbourg 94
Ho Chi Minh City 80
Beijing 75
Hanoi 52
Hong Kong 42
New York 37
Council Bluffs 31
Frankfurt am Main 24
Helsinki 24
Santa Clara 22
Bordighera 20
Mexico City 18
Los Angeles 16
Tokyo 15
Milan 14
Haiphong 13
Rome 13
Boardman 11
St Louis 11
Da Nang 8
São Paulo 8
Biên Hòa 7
Chicago 7
Zurich 7
Amsterdam 6
Guangzhou 6
Johannesburg 6
Kingston 6
Madrid 6
Montreal 6
Nairobi 6
Tianjin 6
Toronto 6
Bari 5
Denver 5
Des Moines 5
Karachi 5
Miami 5
Rio de Janeiro 5
Santiago 5
Baku 4
Buffalo 4
Dublin 4
Hải Dương 4
Karbala 4
Ninh Bình 4
San Francisco 4
Amman 3
Baghdad 3
Belgrade 3
Can Tho 3
Cardiff 3
Changsha 3
Chennai 3
Hangzhou 3
Orem 3
Paris 3
Quảng Ngãi 3
Sorocaba 3
The Bronx 3
Thái Bình 3
Thái Nguyên 3
Vĩnh Long 3
Vũng Tàu 3
Acalanes Ridge 2
Almaty 2
Asunción 2
Bologna 2
Brooklyn 2
Caracas 2
Chongqing 2
City of London 2
Columbus 2
Contagem 2
Cuenca 2
Curitiba 2
Dallas 2
Detroit 2
Jakarta 2
Kyiv 2
Ljubljana 2
London 2
Manchester 2
Manila 2
Miano 2
Naga 2
Nola 2
Oakville 2
Oberengstringen 2
Phoenix 2
Porto Alegre 2
Quezon City 2
Quilmes 2
Totale 12.473
Salva come PNG Salva come JPEG
Nome #
Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MS 263
Finger motor performance as a new quantitative clinical endpoint in multiple sclerosis 241
Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy 237
Neuroprotective features of mesenchymal stem cells. 217
Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. 214
Dysregulation of regulatory CD56bright NK cells/T cells interactions in multiple sclerosis 214
Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption 208
In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma 200
Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification. 199
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. 184
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved? 183
A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study 176
Teriflunomide treatment reduces B cells in patients with MS. 175
Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. 172
Hypothalamic AgRP neurons control hematopoiesis and lymphopoiesis and are activated in experimental MS 170
A case of thyroiditis during natalizumab therapy for multiple sclerosis 170
Three years of experience: the Italian registry and safety data update 168
T-cell trafficking in the central nervous system. 166
Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study 164
Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod 164
Clinical baseline factors predict response to natalizumab: their usefulness in patient selection. 159
Approved drugs for multiple sclerosis: The challenge of choice 158
Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases 157
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis 156
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. 155
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study 154
Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group 153
To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy 150
JCV-DNA testing during natalizumab treatment is complementary to anti-JCV antibodies for PML risk stratification 149
Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report 149
Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation 147
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis 147
Mesenchymal stem cells as treatment for MS - progress to date. 145
Can we kill an extra bird with the same stone? 142
Role of the innate immune system in the pathogenesis of multiple sclerosis. 141
Unraveling the regulatory role of NK cells on T-cell effector functions: Implications for CNS autoimmunity 140
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy 138
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. 136
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome 136
Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab 135
Wernicke's syndrome during parenteral feeding: not an unusual complication. 134
Do NK cells play a role in the possible association between natalizumab treatment and the development of melanoma? 134
Regulatory Functions of Natural Killer Cells in Multiple Sclerosis 133
Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution 133
MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis 131
Impact of treatment on cellular immunophenotype in MS: A cross-sectional study 127
IL-27 imparts immunoregulatory function to human NK cell subsets. 126
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 125
The early effect of cladribrine versus fingolimod on clinical and MRI measures in relapsing remitting multiple sclerosis 123
Assessing upper limb function in Multiple Sclerosis by an engineered glove 123
A pilot study comparing myelin measurements from [18F]-Florbetaben PET and quantitative T1 map imaging in multiple sclerosis (MS) 122
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study 122
The short-chain fatty acid butyrate decreases the regulatory function of human natural killer cells and promotes their maturation 121
Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy 119
Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study 119
Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study 118
Dysregulation of regulatory CD56 (bright) NK cells/T cells interactions in multiple sclerosis 117
Long-term disability progression in primary progressive multiple sclerosis: A 15-year study 117
Epstein-Barr-negative MS: a true phenomenon? 115
The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL 115
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies 113
Natural killer cells are functionally defective in multiple sclerosis 112
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks 112
Multiple sclerosis and autoimmune diseases: epidemiology and HLA-DR association in North-east Italy. 112
Health-related quality of life in multiple sclerosis: Effects of natalizumab 110
Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis 110
CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis 109
Towards clinical application of mesenchymal stem cells for treatment of neurological diseases of the central nervous system. 109
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks 108
Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey 107
Impaired suppressor function of NK cells in multiple sclerosis 106
Aging with multiple sclerosis: Clinical characterization of an elderly population, a cross-sectional study 105
Enhancing natural killer cells is beneficial in multiple sclerosis - Yes 101
Interferon beta potentiates the therapeutic activity of mesenchymal stem cells 100
Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: who gains from it? 97
Impaired suppressor function of CD56bright NK cells in early multiple sclerosis 96
Tailoring B cell depletion therapy in MS according to memory B cell monitoring 96
Effect of ocrelizumab treatment on retinal atrophy: preliminary results from a single-center observational study 95
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study 93
Beyond steady-state amyloid PET to detect demyelination in multiple sclerosis (MS) 93
Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic? 92
A real-world study of alemtuzumab in a cohort of Italian patients 91
COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments 90
Immune Soluble Factors in the Cerebrospinal Fluid of Progressive Multiple Sclerosis Patients Segregate Into Two Groups 89
The effect of Cladribine and Fingolimod treatments on retinal atrophy 88
CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis 88
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies 88
MESEMS: a randomized, double blind placebo-controlled cross-over study to evaluate safety and efficacy of intravenous administration of autologous mesenchymal stem cells in patients with multiple sclerosis 87
Multivariate clinically isolated syndrome (CIS) risk factor study: towards individual prognosis and treatment indication in CIS 87
Noradrenergic control of bone marrow and thymus by AgRP neurons is impaired in experimental multiple sclerosis 84
Mesenchymal stem cells for multiple sclerosis: effect of treatment on peripheral immune cells 84
Mesenchymal stem cells for the treatment of neurological diseases: Immunoregulation beyond neuroprotection 81
Nonfunctional natural killer regulatory cells in multiple sclerosis 79
Effect of SARS-CoV-2 vaccination on natural killer cell responses in multiple sclerosis 78
Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives 73
Cladribine Tablets Mode of Action, Learning from the Pandemic: A Narrative Review 72
Relapsing meningitis and limbic encephalitis in anti-AQP4-Ab-associated neuromyelitis optica spectrum disorder 69
Family Functioning and Multiple Sclerosis: preliminary data of a Multicentric Italian Project 69
To switch therapies in RRMS: why and when? A real-life multicentre study. 68
Mesenchymal Stem/Stromal Cells for Multiple Sclerosis and Other Neurological Diseases 67
Totale 13.014
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.872
article - articoli 48.057
book - libri 0
conference - conferenze 471
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 344
Totale 97.744
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202172 0 0 0 0 0 0 0 0 0 0 0 72
2021/20221.094 45 28 84 111 44 94 40 252 74 113 66 143
2022/2023960 99 74 15 78 149 163 6 67 171 15 102 21
2023/2024765 41 84 9 88 66 84 53 70 69 18 46 137
2024/20252.508 104 214 96 158 294 293 262 421 121 138 183 224
2025/20264.027 510 114 244 388 538 343 592 247 268 432 269 82
Totale 14.191